ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy

References

• Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170–177.
   PubMed Web of Science ®Google Scholar
• Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–249.
   PubMed Web of Science ®Google Scholar
• Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517–525.
   PubMed Web of Science ®Google Scholar
• Grabowski JP, Sehouli J. Current management of ovarian cancer. Minerva Med. 2015;106:151–156.
   PubMed Web of Science ®Google Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765.
   PubMed Web of Science ®Google Scholar
• Hensley MA, Chi D. Ovarian and fallopian-tube cancer. In: Handbook of gynecologic oncology [Internet]. London: Martin Dunitz; 2002.
   Google Scholar
• Or Knudsen A, Schledermann D, Nyvang GB, et al. Trends in gynecologic cancer among elderly women in Denmark, 1980–2012. Acta Oncol. 2016;55:65–73.
   PubMed Web of Science ®Google Scholar
• Anisimov VN. Biology of aging and cancer. Cancer Control. 2007;14:23–31.
   PubMedGoogle Scholar
• Leth-Larsen R, Terp MG, Christensen AG, et al. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med. 2012;18:1109–1121.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Schischmanoff O, Poupardin C, et al. Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis. 2013;45:245–250.
   PubMedGoogle Scholar
• Tsao AS, Liu S, Lee JJ, et al. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012;7:1645–1652.
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Hallas J, Friis S, et al. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106:1353–1360.
   PubMed Web of Science ®Google Scholar
• Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control. 2007;14:44–56.
   PubMedGoogle Scholar
• Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32:2587–2594.
   PubMed Web of Science ®Google Scholar
• Szajnik M, Czystowska-Kuzmicz M, Elishaev E, et al. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn. 2016;16:811–826.
   PubMed Web of Science ®Google Scholar
• Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics – a bioconductor package for quality assessment of microarray data. Bioinformatics (Oxford, England). 2009;25:415–416.
   PubMed Web of Science ®Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England). 2003;19:185–193.
   PubMed Web of Science ®Google Scholar
• Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.
   PubMed Web of Science ®Google Scholar
• Atlas HP. The human protein atlas; [cited 2018 Jun 15]. Available from: https://www.proteinatlas.org/
   Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017; 357. DOI: 10.1126/science.aan2507
   Google Scholar
• Lanczky A, Nagy A, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160:439–446.
   PubMed Web of Science ®Google Scholar
• Miura K, Jacques KM, Stauffer S, et al. ARAP1: a point of convergence for Arf and Rho signaling. Mol Cell. 2002;9:109–119.
   PubMed Web of Science ®Google Scholar
• Daniele T, Di Tullio G, Santoro M, et al. ARAP1 regulates EGF receptor trafficking and signalling. Traffic. 2008;9:2221–2235.
   PubMed Web of Science ®Google Scholar
• Simova S, Klima M, Cermak L, et al. Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. Apoptosis. 2008;13:423–436.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.
   PubMed Web of Science ®Google Scholar
• Szajnik M, Szczepanski MJ, Elishaev E, et al. 17beta hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma. Gynecol Oncol. 2012;127:587–594.
   PubMed Web of Science ®Google Scholar
• Dong Y, Loessner D, Irving-Rodgers H, et al. Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis. 2014;31:135–147.
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Shih Ie M. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol. 2007;17:436–443.
   PubMed Web of Science ®Google Scholar
• Rutten MJ, Dijk F, Savci-Heijink CD, et al. HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J Immunol Res. 2014;2014:1.
   Google Scholar
• Zorn KK, Tian C, McGuire WP, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 2009;115:1028–1035.
   PubMed Web of Science ®Google Scholar
• Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–1452.
   PubMed Web of Science ®Google Scholar
• Suri A, Saini S, Sinha A, et al. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology. 2012;1:1194–1196.
   PubMed Web of Science ®Google Scholar
• Garg M, Chaurasiya D, Rana R, et al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res. 2007;13:1421–1428.
   PubMed Web of Science ®Google Scholar
• Jagadish N, Fatima R, Sharma A, et al. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. Tumour Biol. 2018;40:101042831877365.
   Google Scholar
• Garg M, Kanojia D, Salhan S, et al. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer. 2009;115:2671–2683.
   PubMed Web of Science ®Google Scholar
• Kanojia D, Garg M, Gupta S, et al. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:630–639.
   PubMed Web of Science ®Google Scholar
• Garg M, Kanojia D, Khosla A, et al. Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res. 2008;68:8240–8248.
   PubMed Web of Science ®Google Scholar
• Hetland TE, Nymoen DA, Emilsen E, et al. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecol Oncol. 2012;126:460–465.
   PubMed Web of Science ®Google Scholar
• Johansson K, Jarvliden J, Gogvadze V, et al. Multiple roles of microsomal glutathione transferase 1 in cellular protection: a mechanistic study. Free Radic Biol Med. 2010;49:1638–1645.
   PubMed Web of Science ®Google Scholar